What’s New
Explore latest events, medical insights and trends.
Attenuating the atopic march: Meta Analysis of The Dupilumab Atopic Dermatitis Database for Incident Allergic Events
Read more
Rare diseases are more common than most people imagine
Rare Disease Day raises awareness for the 300 million people worldwide living with a rare disease, along with their families and carers. Over 6,000 rare diseases are characterized by a wide range of conditions and symptoms that can vary not only between diseases but also among individuals with the same condition. Take the opportunity to support equitable access to diagnosis, treatment, healthcare, social support for those affected by rare diseases.
Nirsevimab: Revolutionizing RSV Prevention for All Infants
Join us for an insightful RSV Prevention event featuring expert presentations on the latest advances in respiratory syncytial virus prevention strategies for all infants. Gain valuable insights through four comprehensive video presentations, into systematic reviews of effectiveness data, healthcare system implementation approaches, global prevention strategies, and the significant impact of RSV prevention on reducing disease burden in pediatric populations.
United in RARE: Advancing LSDs Care Across ASIA
The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.
Type 2 Asthma Remission: Latest Data
Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.
LIBERTY AD CHRONOS (18+ years)
LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with
moderate-to-severe atopic dermatitis
LIBERTY AD SOLO-CONTINUE (18+ years)
LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.
Patient-Video
Request-form